Detailansicht

Wissensnetz

Person

Gisa Ellrichmann (1978-)

Ärztin

Name	Gisa Ellrichmann
Zeit	1978- (Lebensdaten)
Ort	Hagen (Geburtsort) Deutschland
Geschlecht	weiblich
Akademischer Grad bzw. Titel	PD Dr. med.
Beruf	Ärztin (charakteristischer Beruf) Neurologin
Weitere Angaben	Dissertation; 2008; Medizinische Fakultät; Ruhr-Universität Bochum; St. Josef-Hospital Bochum, Neurologische Klinik; Fachärztin für Neurologie; Habilitationsschrift 2018, Medizinische Fakultät, Ruhr-Universität Bochum; seit 09.2016, Oberärztliche Leiterin, Neurologische Intensivstation, St. Josef-Hospital Bochum
Datensatztyp	Person
GND-Nummer	134107608
Datensatz-ID	134107608
Beteiligt an alle anzeigen NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62 Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells Novel variants in a patient with late-onset hyperprolinemia type II: diagnostic key for status epilepticus and lactic acidosis Author Correction: Laquinimod treatment in the R6/2 mouse model A protein quality control pathway regulated by linear ubiquitination Brainstem encephalitis with low-titer acetylcholine receptor antibodies mimicking myasthenia gravis Novel variants in a patient with late-onset hyperprolinemia type II : diagnostic key for status epilepticus and lactic acidosis Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders Neuroimmunologische Register in Deutschland Laquinimod treatment in the R6/2 mouse model Die Rolle des Immunsystems bei neurodegenerativen Prozessen im Zentralnervensystem als Basis neuer Therapieansätze Insight into metabolic 1H-MRS changes in natalizumab induced progressive multifocal leukoencephalopathy brain lesions Metabolic profiles by \(^{1}\)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML) Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease Vorkommen und Wertigkeit von Oberfrequenzen in der 24-Stunden-Elektromyographie und Accelerometrie bei Parkinson und essentiellem Tremor

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Gisa Ellrichmann (1978-)

NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62

Immunomodulatory and anti-oxidative effect of the direct TRPV1 receptor agonist capsaicin on Schwann cells

Novel variants in a patient with late-onset hyperprolinemia type II: diagnostic key for status epilepticus and lactic acidosis

Author Correction: Laquinimod treatment in the R6/2 mouse model

A protein quality control pathway regulated by linear ubiquitination

Brainstem encephalitis with low-titer acetylcholine receptor antibodies mimicking myasthenia gravis

Novel variants in a patient with late-onset hyperprolinemia type II : diagnostic key for status epilepticus and lactic acidosis

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

Neuroimmunologische Register in Deutschland

Laquinimod treatment in the R6/2 mouse model

Die Rolle des Immunsystems bei neurodegenerativen Prozessen im Zentralnervensystem als Basis neuer Therapieansätze

Insight into metabolic 1H-MRS changes in natalizumab induced progressive multifocal leukoencephalopathy brain lesions

Metabolic profiles by \(^{1}\)H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease

Increase of angiotensin II type 1 receptor auto-antibodies in Huntington’s disease

Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation

Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation

Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease

Vorkommen und Wertigkeit von Oberfrequenzen in der 24-Stunden-Elektromyographie und Accelerometrie bei Parkinson und essentiellem Tremor